Q2 revenue and net profit rise as margins narrow

Ebitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹1282.70

prior close

₹1283.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.6%-0.4% vs market

Pharmaceuticals peers, median of 152sector-0.2%+0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.5

15m

-0.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+0.6-0.4-0.2+0.3

Next day

+0.9+0.4+0.4-0.1+1.0

-1.9+1.0-2.9+0.2-2.1

-6.2+0.4-6.6+0.4-6.5

-6.6-0.1-6.5-0.0-6.6

-6.6+0.2-6.8+0.6-7.2

-6.1-0.9-5.2-1.3-4.8

15d

-3.2+0.4-3.6-2.3-0.9

-2.6+1.3-3.9-3.8+1.3

-1.0+0.3-1.3-5.7+4.7

-3.5-2.6-0.8-12.5+9.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 revenue rose 9.8% to Rs 88.1 billion; net profit rose 14% to Rs 14.4 billion. Pre-tax profit fell 4% to Rs 18.35 billion as gross margin narrowed to 54.7% from 59.6% and EBITDA margin to 26.7% from 28.4%. H1 revenue rose 10.6% to Rs 173.5 billion. NRT and branded growth helped, but North America price erosion, higher SG&A and a Rs 695 million VAT provision hurt margins. USFDA observations and tax reviews add risk.

Likely market impact

Revenue and net profit grew, but weaker margins, North America price erosion, USFDA observations and tax reviews may limit stock upside.